9.61
-0.62 (-6.06%)
| Previous Close | 10.23 |
| Volume | 1,859,962 |
| Price / Sales | 6.16 |
| Price / Book | 1.68 |
| 52 Weeks Range |
| Profit Margin | -198.84% |
| Operating Margin (TTM) | -182.09% |
| Diluted EPS (TTM) | -8.91 |
| Quarterly Revenue Growth (YOY) | 27.30% |
| Total Debt/Equity (MRQ) | 67.12% |
| Current Ratio (MRQ) | 4.88 |
| Operating Cash Flow (TTM) | -281.85 M |
| Levered Free Cash Flow (TTM) | -185.65 M |
| Return on Assets (TTM) | -16.99% |
| Return on Equity (TTM) | -57.76% |
News Mood
-
Ginkgo Bioworks Holdings Inc (DNA) Q3 2026 Earnings Call Highlights: Cost Cuts, First Big ...
11 Nov, 11:05PM
-
Ginkgo Bioworks (DNA) Q3 2026 Earnings Call Transcript
06 Nov, 1:47AM
-
Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo
05 Nov, 3:05PM
AIStockmoo Score
| Value 30% | -0.7 |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Return on Capital info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | 0.2 |
| No clear trend over the past year. Far below its 52-week high. info | |
| No clear trend: the price is moving around its moving averages. It is close to them. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.6 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Holdings' Sentiment info | NA |
| Smart Money 20% | 4.9 |
| Institutions net +7.36% of shares in their latest 13F filings: 91 holders increased, 79 decreased (quarter to 30 Sep 2026). info | |
| Insider Activity info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Above its medium-term trend line. info | |
| Price is high against its 52-week average. Down over 5 years. info | |
| Short-term momentum falling. info | |
| Price is near support. info | |
| Final Score | 0.91 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Ginkgo Bioworks Holdings, Inc. | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| DNA | - | - | - | 1.68 | 0.9 |
| ADCT | - | - | - | - | -1.3 |
| ANVS | - | - | - | 16.34 | -0.5 |
| ANRO | - | - | - | 4.13 | 0.0 |
| RCUS | - | - | - | 6.21 | -1.8 |
| NUVB | - | - | - | 6.18 | -1.1 |
Select this tab to load the latest available analysis.
|
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.88% |
| % Held by Institutions | 77.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Erste Asset Management Gmbh | 30 Jun 2026 | 2,536,939 |
| Forbes J M & Co Llp | 30 Sep 2026 | 977,371 |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 77.35%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 91 | 5,547,261 |
| Decreased | 79 | 2,036,547 |
| New | 26 | 1,009,869 |
| Sold out | 31 | 546,570 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
Ginkgo Bioworks Holdings Inc (DNA) Q3 2026 Earnings Call Highlights: Cost Cuts, First Big ...
Ginkgo Bioworks Holdings Inc (DNA) narrowed its net loss 44% and landed Novo Nordisk as its first autonomous lab customer, even as revenue slipped 6% and cash burn stayed high. |
| 07 Nov 2026 | Yahoo Finance |
Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors
Ginkgo's shift to physical data for AI labs is the thread tying its cost discipline to its hardware ambitions. |
| 07 Nov 2026 | Yahoo Finance |
Ginkgo Bioworks Q3 Earnings Call Highlights
Ginkgo Bioworks (NYSE:DNA) reported lower third-quarter revenue but narrowed its loss as restructuring-related expense cuts took hold, while executives highlighted new customers for its autonomous laboratory systems and cloud-based lab services. Revenue from continuing operations fell 6% year over… |
| 06 Nov 2026 | Yahoo Finance |
Ginkgo Bioworks Holdings, Inc. Q3 2026 Earnings Call Summary
Moby summary of Ginkgo Bioworks Holdings, Inc.'s Q3 2026 earnings call… |
| 06 Nov 2026 | Yahoo Finance |
Ginkgo Bioworks (DNA) Q3 2026 Earnings Call Transcript
Ginkgo cut its quarterly loss 44% as it pivots to autonomous labs. |
| 05 Nov 2026 | Yahoo Finance |
Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo
BOSTON, November 05, 2026--Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the third quarter of 2026 that ended September 30, 2026. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial… |
| 29 Oct 2026 | Yahoo Finance |
Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.74 in the latest trading session, marking a -4.35% move from the prior day. |
| 24 Oct 2026 | Yahoo Finance |
What Ginkgo Bioworks Bears Saw Before The Fall
Ginkgo Bioworks has just agreed to open its Boston autonomous lab to National Science Foundation X-Labs teams, while also wiring Araceli’s high-speed imaging gear into its Nebula setup. For Ginkgo Bioworks shareholders, the loss over the past year was 26.4%, including dividends. If you had… |
| 20 Oct 2026 | Yahoo Finance |
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.86 at the closing of the latest trading day, reflecting a -2.09% change compared to its last close. |
| 14 Oct 2026 | Yahoo Finance |
Ginkgo Bioworks (DNA) Stock Fair Value Edges Higher After Analysts Reassess AI Demand
The latest analyst update on Ginkgo Bioworks Holdings includes a higher fair value estimate of US$8 and at least one price target set at US$11, which points to a reassessment of what investors might be willing to pay for the stock. That shift is closely linked to recent commentary that combines… |
| 14 Oct 2026 | Yahoo Finance |
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $11.53, indicating a -1.96% shift from the previous trading day. |
| 08 Oct 2026 | Yahoo Finance |
Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
Araceli Biosciences and Ginkgo Bioworks (NYSE: DNA) today announced the integration of Araceli's Endeavor® high-content imaging instrument into Nebula, Ginkgo's autonomous lab in Boston. The Endeavor, the world's fastest high-content imaging system, brings cellular imaging with real-time analysis… |
| 07 Oct 2026 | Yahoo Finance |
Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $11.47, moving 7.57% from the previous trading session. |
| 05 Oct 2026 | Yahoo Finance |
This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled
Eli Lilly is partnering with Ginkgo Bioworks on drug discovery. |
| 29 Sep 2026 | Yahoo Finance |
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
BOSTON, September 29, 2026--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium… |
| 25 Sep 2026 | Yahoo Finance |
What Needs To Be True To Buy Twist Bioscience Stock Now?
A $10,000 holding in Twist Bioscience (TWST) a year ago is worth about $66,600 today. The same sum in the S&P 500 would be worth about $11,700. The company sells made-to-order DNA to drug makers and research labs. Its sales grow fast, but it still loses money. The price now counts on that growth… |
| 23 Sep 2026 | Yahoo Finance |
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $8.58, marking a -8.43% move from the previous day. |
| 18 Sep 2026 | Yahoo Finance |
Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?
Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
| Show more | ||
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |